Similar articles

• New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.

  Mason RG. Mason RG. J R Soc Promot Health. 2003 Jun;123(2):79-80. doi: 10.1177/146642400312300209. J R Soc Promot Health. 2003. PMID: 12852189 No abstract available.
• Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.

  Kloner RA. Kloner RA. Circulation. 2004 Nov 9;110(19):3149-55. doi: 10.1161/01.CIR.0000146906.42375.D3. Circulation. 2004. PMID: 15533876 Review. No abstract available.
• Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.

  Seftel AD. Seftel AD. Curr Pharm Des. 2005;11(31):4047-58. doi: 10.2174/138161205774913426. Curr Pharm Des. 2005. PMID: 16378510 Review.
• Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.

  Kloner RA. Kloner RA. Am J Cardiol. 2005 Dec 26;96(12B):42M-46M. doi: 10.1016/j.amjcard.2005.07.011. Epub 2005 Dec 5. Am J Cardiol. 2005. PMID: 16387566 Review.
• Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.

  Vickers MA, Satyanarayana R. Vickers MA, et al. Int J Impot Res. 2002 Dec;14(6):466-71. doi: 10.1038/sj.ijir.3900910. Int J Impot Res. 2002. PMID: 12494279